<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2021-05666_2-255-12262</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Probing the future of KAF156/Ganaplacide, a next-generation replacement for artemisinin in antimalarial combination therapy</narrative>
   <narrative xml:lang="SV">Testa framtiden f&#xF6;r KAF156/Ganaplacide, en n&#xE4;sta generation ers&#xE4;ttning f&#xF6;r artemisinin i antimalarial kombinationsbehandling</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">KAF156/Ganaplacide (Novartis) is a promising antimalarial, with one-digit nanomolar IC50s against Plasmodium falciparum, planned as a longer half-life replacement of artemether in combination with lumefantrine (LUM). It will hit the field by the second half of the 2020s. P.&#xA0;falciparum can develop resistance against KAF156 in vitro, through mutations in a new transporter, pfCARL. We will explore KAF156 resistance with the objective of predicting its future clinical impact, and gather knowledge supporting mitigating measures.Workplan:To develop KAF156 resistance in vitro, followed by whole genome sequencing to identify causal mutations.To test the resistant parasites reproducing the patient real-life KAF156 pharmacokinetics. Resistance defined by the parasite capacity to recrudesce, as in vivo - an objective link between in vitro drug resistance data and in vivo reality.To explore the pharmacodynamics characteristics of KAF156 in combination with LUM (isobolgrams), and probe mechanisms of resistance with putative inhibitors.To explore SNP selection upon treatment: (a) Are pfcarl mutations selected in vivo by the KAF156/LUM combination? Does KAF156-LUM select LUM resistance associated pfmdr1 mutations? We will analyze the first African large phase III KAF156-LUM efficacy trial, to be performed in 2022-2025 in Mali. (b) In parallel, archive Artemether-Lumefantrine (AL) trials will be revisited: can LUM select for pfcarl mutations by itself?</narrative>
   <narrative xml:lang="SV">Sedan starten p&#xE5; &#xE5;rhundradet har malarians d&#xF6;dstal minskat kraftigt, till stor del beroende p&#xE5; inf&#xF6;randet av artemisinin kombinations terapi (ACT). Tyv&#xE4;rr hittas nu ACT resistens hos parasiten.En insats f&#xF6;r att uppt&#xE4;cka och utveckla nye effektiva malariamedel har p&#xE5;g&#xE5;tt o m&#xE5;nga &#xE5;r. En av de mest lovande kandidaterna heter KAF156. KAF156 har visat sig vara ett oralt administrerbart, mycket potent malariamedel som inte associerats till signifikanta biverkningar. An KAF156-lumefantrin studie planeras vara tillg&#xE4;nglig inom 5 &#xE5;rs tid och f&#xF6;rv&#xE4;ntas vara en stor tillg&#xE5;ng i den kampen mot malaria under n&#xE4;sta &#xE5;rtionde. Men tyv&#xE4;rr har KAF156 en akillesh&#xE4;l. Studier har visat att resistenta parasiter enkelt selekteras fram in vitro. Den h&#xE4;r fenotypen &#xE4;r associerad till mutationer i genen pfcarl. Det &#xE4;r essentiellt att unders&#xF6;ka om dessa resistenta parasiter ocks&#xE5; &#xE4;r resistenta in vivo, n&#xE4;r parasiterna exponeras f&#xF6;r terapeutiska niv&#xE5;er av KAF156. I det h&#xE4;r projektet kommer vi att f&#xF6;rs&#xF6;ka b&#xE4;ttre f&#xF6;rst&#xE5; basen f&#xF6;r den resistenta fenotypen, eftersom den verkar uppst&#xE5; efter mer genetiska f&#xF6;r&#xE4;ndringar &#xE4;n bara de som uppst&#xE5;r I pfcarl genen.Projektet kommer att starta genom att selektera resistenta parasiter I laboratorium genom att exponera parasit f&#xF6;r succesivt &#xF6;kande KAF156 koncentrationer eller genom att exponera dem f&#xF6;r h&#xF6;ga KAF156 koncentrationer och d&#xE5; detektera parasit som redan &#xE4;r resistenta. Resistenta parasite kommer d&#xE4;refter att f&#xE5; sitt genom sekvenserat och det kommer att j&#xE4;mf&#xF6;ras med icke resistenta parasiters genom. Nya mutationer som uppst&#xE5;tt under kommer att detekteras. Vi f&#xF6;rv&#xE4;ntas oss att mutationer inte bara uppst&#xE5;tt I pfcarl genen utan ocks&#xE5; I andra gener.N&#xE4;sta fas &#xE4;r att exponera parasiterna f&#xF6;r samma koncentrationer av KAF156 som i patienternas blod under klinisk behandling. F&#xF6;r att g&#xF6;ra detta kommer vi att anv&#xE4;nda en ny approach. Med hj&#xE4;lp av datorkontrollerade h&#xF6;g-precision pumpar kommer vi att simulera l&#xE4;kemedlets verkliga farmakokinetik. Helt resistenta parasit b&#xF6;r d&#xE5; lunna t&#xE5;la en full simulerad behandlingscykel. Dessa experiment kommer att svara p&#xE5; en viktig fr&#xE5;ga, om den observerade in vitro fenotypen &#xE4;r en reell indikation f&#xF6;r hur l&#xE4;kemedlet kommer att fundera in vivo.Vi vill ocks&#xE5; f&#xF6;rst&#xE5; mer runt FKAF156 farmakologiska egenskaper, som inte har studerats I detalj men som &#xE4;r av praktisk betydelse. Finns synergieffekter med andra malariamedel, t.ex. lumefantrin. G&#xF6;r KAF156 resistent parasiterna mer k&#xE4;nsliga f&#xF6;r andra malariamedel, vilken skulle &#xF6;ppna upp f&#xF6;r framtida kombinationsbehandlingar.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2022-01-01" type="1"></activity-date>
  <activity-date iso-date="2024-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="ML" percentage="100">
   <narrative xml:lang="EN">Mali</narrative>
  </recipient-country>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12262" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Malaria control</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">86764.0989168581</value>
  </budget>
  <budget>
   <period-start iso-date="2023-01-01"></period-start>
   <period-end iso-date="2023-12-28"></period-end>
   <value currency="USD" value-date="2023-01-01">80934.4285231261</value>
  </budget>
  <budget>
   <period-start iso-date="2024-01-01"></period-start>
   <period-end iso-date="2024-12-28"></period-end>
   <value currency="USD" value-date="2024-01-01">92593.6527183481</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-11-25"></transaction-date>
   <value currency="USD" value-date="2021-11-25">520584.3603166645</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
